Embolx's New G-Code Improves Access to Advanced Catheter Procedures

Embolx Secures New HCPCS Level II G-Code for Enhanced Patient Care

Embolx, Inc., a frontrunner in the development of advanced microcatheter technology specifically designed for targeted embolization procedures, recently announced a significant milestone. The Centers for Medicare & Medicaid Services (CMS) has officially established a new HCPCS Level II code, G0577, which will cover the Sniper® procedures performed in a physician office or an office-based lab (OBL). This new reimbursement code came into effect on July 1, 2026, marking a pivotal change in how these procedures can be accessed by patients.

Embolx has been at the forefront of this initiative, having worked diligently alongside CMS for over a year to secure this vital code. The company is optimistic about the potential impact of this new reimbursement pathway in enhancing patient accessibility to essential pressure-generating catheter procedures in a more cost-effective environment.

Michael Allen, CEO of Embolx, expressed gratitude towards CMS for their collaboration throughout this process, as well as appreciation for the contributions made by physician advisors, reimbursement consultants, attorneys, and the Embolx staff. He emphasizes that the new code is set to facilitate a better healthcare experience as patients will now have access to advanced embolization techniques at a lower-cost site of service without sacrificing the quality of care.

The development of this code signifies a broader trend of performing interventional oncology procedures in office-based settings. This shift aligns with feedback from medical professionals who believe that lower costs combined with efficient logistics in an OBL environment will ultimately benefit patients, thus ensuring they receive high-quality care.

Dr. Aaron Fischman, a renowned Professor of Interventional Radiology, Urology, and Surgery at Mount Sinai, highlighted the advantages of this development. He stated, "I congratulate Embolx for their efforts to expand essential care to the Office-Based Lab (OBL) setting. Our center has utilized the Sniper microcatheter for years because it consistently improves clinical outcomes for our patients. The introduction of the new G-code, G0577, is a significant milestone that will further support the delivery of high-quality interventional oncology care."

Balloon occlusion pressure embolization is a technique used primarily for treating conditions such as primary liver cancer and prostate artery embolization among others. Emphasizing the importance of this procedure, Embolx continues to innovate and advance their technology to serve patients better.

Embolx is dedicated to transforming healthcare through its groundbreaking medical devices, including the Sniper Balloon Occlusion Microcatheter. The company's mission is to provide precise, effective, and efficient therapeutic delivery methods for various medical conditions, particularly cancer.

In conclusion, the establishment of G0577 represents a monumental advancement for Embolx and interventional oncology professionals across the country. With this new code, patients are expected to gain enhanced access to critical treatments that not only save costs but also improve overall clinical outcomes. As the healthcare landscape continues to shift towards more patient-centric approaches, Embolx remains committed to leading the charge with innovative technologies that redefine medical care standards.